Chrysa Mineo has over 26 years of experience in biotechnology, serving most recently on the executive team of Receptos as Senior Vice President, Corporate Development. Ms. Mineo joined Receptos in 2009 prior to the Series A funding round, and she led business development efforts to secure partnership for Receptos’ Phase 3 immunology/GI candidate ozanimod, which efforts ultimately resulted in the acquisition of Receptos by Celgene for $7.8 billion in July 2015. During her tenure at Receptos and through collaborations with AbbVie, Ono, Lilly and Janssen Pharmaceuticals, Ms. Mineo in-licensed a P2-ready clinical candidate and raised significant non-dilutive capital for Receptos. She also played a key role in the 2013 Receptos Initial Public Offering (IPO), leading the S-1 registration filing. Receptos ultimately raised over $700M in equity capital markets to advance multiple drug development programs in neuro-immunology and GI indications. Prior to Receptos, Ms. Mineo spent 12 years with San Diego-based Neurocrine Biosciences in roles of increasing business development responsibility for neuroscience and metabolic-oriented drug development programs. Prior to Neurocrine, Ms. Mineo served in various capacities in research, marketing and business development for such companies as Amgen, DNAX Research Institute, Schering Plough and Baxter Biotech. She began her career in 1987 with Amgen as a member of a cellular biology team identifying a therapeutic role for Neupogen®. Ms. Mineo holds a B.S. in Zoology from the University of California, Davis and received her M.B.A. from Duke University’s Fuqua School of Business.